1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Adverum, 4D Molecular Present Dueling Phase II Datasets In Wet AMD

 
• By Joseph Haas

The two biotechs each hope to offer an Eylea-sparing regimen to wet age-related macular degeneration patients with gene therapies that induce natural production of aflibercept.

Human eye
Adverum, 4D Molecular each hope to bring a gene therapy to market for wet AMD • Source: Shutterstock

Two San Francisco Bay-area biotechs – Adverum Biotechnologies, Inc. and 4D Molecular Therapeutics Inc. – presented updated Phase II readouts on 17 July for their gene therapy candidates for wet age-related macular degeneration (AMD), with each company saying it plans to move its candidate into Phase III during 2025.

Key Takeaways

  • Competing biotechs Adverum and 4D Molecular Therapeutics reported Phase II data for their gene therapies that they hope will offer a treatment-burden reduction in wet AMD.

    ...

Presenting at the American Society of Retinal Specialists meeting in Stockholm, Adverum called its candidate ixoberogene soroparvovec (ixo-vec) potentially best-in-class and tried to dampen prior worries about product safety, while...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from Ophthalmology

Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD

 
• By Alaric DeArment

The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.

Santen Fortifies Glaucoma Strategy With Sepetaprost Japan Filing

 
• By Lisa Takagi

The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.

Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED

 
• By Alaric DeArment

Results from the Phase III THRIVE trial in active thyroid eye disease had analysts calling veligrotug “best-in-class” as they anticipate results from THRIVE-2 in chronic TED later this year.